TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07863024: A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07863024 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07863024 Rescue Dossier →